3M CO MMM

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived NYSE

Last close 173.46 2026-10-23
Market cap $89.46B 2026-06-30 share count
52-week range 139.34 - 184.90

Valuation FY2025 figures against the last close

P/S3.6x
P/E28.9x
P/FCF64.1x
EV/EBITDA16.3x
Dividend yield1.7%
Diluted EPS6.00

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $24.95B$24.57B$24.61B$26.16B$35.35B$32.18B$32.14B$32.77B$31.66B$30.11B
Cost of revenue $14.99B$14.45B$14.98B$15.85B$18.80B$16.61B$17.14B$16.68B$16.05B$15.12B
Gross profit $9.96B$10.13B$9.63B$10.31B$16.56B$15.58B$15.00B$16.08B$15.60B$14.99B
R&D —$700.0M$700.0M$800.0M$1.20B$1.10B$1.25B$1.25B$1.35B$1.25B
SG&A $4.00B$4.22B$19.20B$7.23B$7.20B$6.93B$7.03B$7.60B$6.63B$6.31B
Total operating expenses $20.32B$19.75B$35.30B$21.79B$27.99B$25.02B$25.96B$25.56B$23.96B$23.08B
Operating income $4.63B$4.82B-$10.69B$4.37B$7.37B$7.16B$6.17B$7.21B$7.69B$7.03B
Interest expense $946.0M$1.19B$941.0M$462.0M$488.0M$529.0M$448.0M$350.0M$322.0M$199.0M
Pre-tax income $4.21B$4.82B-$11.27B$4.20B$7.20B$6.79B$5.64B$7.00B$7.55B$7.05B
Income tax $1.00B$804.0M$2.87B$188.0M$1.28B$1.34B$1.11B$1.64B$2.68B$2.00B
Net income $3.25B$4.17B-$7.00B$5.78B$5.92B$5.45B$4.52B$5.35B$4.86B$5.05B
EPS, basic 6.057.58-12.6310.2110.239.437.839.098.138.35
EPS, diluted 6.007.55-12.6310.1810.129.367.728.897.938.16
Shares, diluted (wtd. avg.) 541.3M552.4M553.9M567.6M585.3M582.2M585.1M602.0M612.7M618.7M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $5.24B$5.60B$5.93B$3.65B$4.56B$4.63B—$2.85B$3.05B$2.40B
Short-term investments —————$404.0M$98.0M$380.0M$1.08B—
Receivables $3.53B$3.19B$3.60B$4.53B$4.66B$4.71B$4.79B$5.02B$4.91B$4.39B
Inventory $3.66B$3.70B$3.94B$5.37B$4.99B$4.24B$4.13B$4.37B$4.03B$3.38B
Total current assets $16.39B$15.88B$16.38B$14.69B$15.40B$14.98B$12.97B$13.71B$14.28B$11.73B
Property, plant and equipment $7.10B$7.39B$7.69B$9.18B$9.43B$9.42B$9.33B$8.74B$8.87B$8.52B
Goodwill $6.42B$6.28B$6.38B$6.34B$13.49B$13.80B$13.44B$10.05B$10.51B$9.17B
Other intangibles $1.10B$1.21B$1.32B$4.70B$5.29B$5.83B$6.38B$2.66B$2.94B$2.32B
Total assets $37.73B$39.87B$50.58B$46.45B$47.07B$47.34B$44.66B$36.50B$37.99B$32.91B
Accounts payable $2.70B$2.66B$2.78B$3.18B$2.99B$2.56B$2.23B$2.27B$1.95B$1.80B
Short-term debt $1.67B$1.92B$1.15B$1.94B$1.29B$794.0M$2.79B$1.21B$1.85B$972.0M
Total current liabilities $9.60B$11.26B$15.30B$9.52B$9.04B$7.95B$9.22B$7.24B$7.69B$6.22B
Long-term debt $10.93B$11.12B$13.09B$14.00B$16.06B$17.99B$17.52B$13.41B$12.10B$10.68B
Total liabilities $32.99B$35.97B$45.71B$31.68B$31.95B$34.41B$34.53B$26.65B$26.36B$22.56B
Retained earnings $38.26B$36.80B$37.48B$47.95B$45.82B$43.82B$42.13B$40.64B$39.12B$37.91B
Total equity $4.70B$3.84B$4.87B$14.77B$15.12B$12.93B$10.13B$9.85B$11.62B$10.34B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $2.31B$1.82B$6.68B$5.59B$7.45B$8.11B$7.07B$6.44B$6.24B$6.66B
Depreciation and amortisation $1.31B$1.36B$1.99B$1.83B$1.92B$1.91B$1.59B$1.49B$1.54B$1.47B
Stock-based compensation $225.0M$289.0M$274.0M$263.0M$274.0M$262.0M$278.0M$302.0M$324.0M$298.0M
Capital expenditure $910.0M$1.18B$1.61B$1.75B$1.60B$1.50B$1.70B$1.58B$1.37B$1.42B
Investing cash flow $1.35B-$3.21B-$1.21B-$1.05B-$1.32B-$580.0M-$6.44B$222.0M-$3.09B-$1.40B
Financing cash flow -$4.02B$1.10B-$3.15B-$5.35B-$6.14B-$5.30B-$1.12B-$6.70B-$2.65B-$4.63B
Dividends paid $1.56B$1.98B$3.31B$3.37B$3.42B$3.39B$3.32B$3.19B$2.80B$2.68B
Buybacks $3.25B$1.80B$33.0M$1.46B$2.20B$368.0M$1.41B$4.87B$2.07B$3.75B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000066740-26-000014.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20B 0 20B 40B Revenue, FY2016: 30.1B Gross profit, FY2016: 15B Net income, FY2016: 5B Revenue, FY2017: 31.7B Gross profit, FY2017: 15.6B Net income, FY2017: 4.9B Revenue, FY2018: 32.8B Gross profit, FY2018: 16.1B Net income, FY2018: 5.3B Revenue, FY2019: 32.1B Gross profit, FY2019: 15B Net income, FY2019: 4.5B Revenue, FY2020: 32.2B Gross profit, FY2020: 15.6B Net income, FY2020: 5.4B Revenue, FY2021: 35.4B Gross profit, FY2021: 16.6B Net income, FY2021: 5.9B Revenue, FY2022: 26.2B Gross profit, FY2022: 10.3B Net income, FY2022: 5.8B Revenue, FY2023: 24.6B Gross profit, FY2023: 9.6B Net income, FY2023: -7B Revenue, FY2024: 24.6B Gross profit, FY2024: 10.1B Net income, FY2024: 4.2B Revenue, FY2025: 24.9B Gross profit, FY2025: 10B Net income, FY2025: 3.2B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $30.11B $31.66B $32.77B $32.14B $32.18B $35.35B $26.16B $24.61B $24.57B $24.95B
Gross profit $14.99B $15.60B $16.08B $15.00B $15.58B $16.56B $10.31B $9.63B $10.13B $9.96B
Net income $5.05B $4.86B $5.35B $4.52B $5.45B $5.92B $5.78B -$7.00B $4.17B $3.25B

Recent filings and events

  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed Item 1.01
  • New debt or obligation Item 2.03
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%
SOLV Solventum Corp $14.54B 9.6x 0.9%